Monday 11 May, 2026
This talk addresses key preclinical and early translational challenges in oncology model-informed drug development. It explores emerging immunomodulatory therapies,alongside the…
Read moreAbstracts
Opemalirsen antisense oligonucleotide targeting the APOL1 mRNA provide dose-dependent APOL1 reduction in plasma
Thursday 7 May, 2026
Objectives APOL1-mediated kidney disease (AMKD) is associated with toxic gain of function variants in people of African ancestry with the…
Read moreDEVELOPMENT OF AN INTERSPECIES-SCALED PBPK MODEL AND STRUCTURAL PK–PD FRAMEWORK FOR ABROCITINIB
Thursday 7 May, 2026
Introduction / Objective Abrocitinib is an oral selective Janus kinase 1 (JAK1) inhibitor approved for the treatment of moderate-to-severe atopic…
Read moreOpemalirsen antisense oligonucleotide targeting the APOL1 mRNA does not prolong the QTc interval.
Thursday 7 May, 2026
Objectives Opemalirsen (previously known as AZD2373) is an antisense oligonucleotide (ASO) targeting the APOL1 mRNA. It is currently explored as…
Read moreQuantitative Predictive Check (QPC): A Scalar Framework for Objective and Optimization-Ready VPC Evaluation
Thursday 7 May, 2026
Introduction: Model evaluation in pharmacometrics relies on multiple criteria, including likelihood-based statistics, parameter precision, plausibility of covariate effects, and graphical…
Read moreApplication of a Simulation-Based Diagnostics for Survival Evaluation in Joint Models
Thursday 7 May, 2026
Introduction: Joint modeling methodology that integrates longitudinal biomarkers and time-to-event outcomes has become an essential component of pharmacometric analyses in…
Read moreINTEGRATED POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE MODELING OF ENLICITIDE IN HYPERCHOLESTEROLEMIA PATIENTS SUPPORTS CLINICAL DOSE RECOMMENDATION ACROSS PATIENT SUBGROUPS
Thursday 7 May, 2026
Introduction: Despite the well-established cardiovascular benefit of LDL-cholesterol (LDL-C) lowering, real-world use of PCSK9-targeted therapies remains limited, in part due…
Read moreModel-Informed Drug Development at Sِaudi FDA: Approaches, Applications, and Regulatory Impact
Thursday 7 May, 2026
Title: Model-Informed Drug Development at Sِaudi FDA: Approaches, Applications, and Regulatory Impact Author: Alanood Alkhaldi (1), Jamilah Alnahdi(1), Abdullah Alsultan(2),…
Read moreIs regrowth of Mycobacterium tuberculosis always a sign of phenotypical resistance? A model-based approach to interpret drug instability and the implications for potency estimation in time-kill assays.
Thursday 7 May, 2026
Introduction:The observed regrowth of Mycobacterium tuberculosis (Mtb) in vitro is often attributed to the emergence of phenotypical resistance or relapse-associated…
Read moreMachine learning for covariate imputation – application in a real-world scenario
Thursday 7 May, 2026
Objective: Population pharmacokinetic (PopPK) models describe the changes in drug concentration across diverse patient populations, leveraging covariate effects using a…
Read more